HNSA Stock Price, Performance & Company Data

07:00

09:05

11:15

13:20

15:25

About Hansa Biopharma AB

Hansa Biopharma AB is a biopharmaceutical company headquartered in Lund, Sweden, operating within the healthcare industry. The company specializes in developing immunomodulatory enzyme technology to treat rare immunological conditions. Its leading product, Idefirix, is designed to enable kidney transplants in highly sensitized patients by cleaving immunoglobulin G antibodies. Hansa Biopharma's strategic focus includes expanding its technology platform and gaining regulatory approvals internationally. The company's innovative approach in enzyme-based therapies positions it to address unmet medical needs in transplantation and autoimmunity.

Ticker: Skr HNSA
Sector: Health

Primary listing: XSTO
Employees: 131

Headquarters: Lund, Sweden
Website: www.hansabiopharma.com

HNSA Metrics

BasicAdvanced

kr 4.2B

-kr 7.74

1.58

Bulls say / Bears say

FDA set a PDUFA action date of December 19, 2026 for the imlifidase BLA, marking a critical regulatory milestone en route to potential U.S. approval and commercialization (Reuters)

The €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA substantially strengthens Hansa’s balance sheet and accelerates its global commercial footprint ahead of the U.S. launch (Reuters)

USD 30 million convertible note financing secured from Athyrium Capital extends Hansa’s runway, boosting cash and equivalents to SEK 676.5 million and underpinning pre-launch U.S. activities (Reuters)

First-quarter 2026 revenue plunged 47.8% year-over-year to SEK 34.6 million, reflecting execution challenges following the European commercial reorganization (Reuters)

Operating loss widened to SEK 142.5 million in Q1 2026 from SEK 93.4 million in Q1 2025 as elevated SG&A spend on U.S. launch preparations outpaced modest revenue recovery (Reuters)

Net loss ballooned to SEK 196.3 million in Q1 2026 from SEK 38.8 million a year earlier, intensifying funding pressure and heightening the risk of further dilution (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 2 Aug 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Bulls say / Bears say

FDA set a PDUFA action date of December 19, 2026 for the imlifidase BLA, marking a critical regulatory milestone en route to potential U.S. approval and commercialization (Reuters)

First-quarter 2026 revenue plunged 47.8% year-over-year to SEK 34.6 million, reflecting execution challenges following the European commercial reorganization (Reuters)

Operating loss widened to SEK 142.5 million in Q1 2026 from SEK 93.4 million in Q1 2025 as elevated SG&A spend on U.S. launch preparations outpaced modest revenue recovery (Reuters)

Net loss ballooned to SEK 196.3 million in Q1 2026 from SEK 38.8 million a year earlier, intensifying funding pressure and heightening the risk of further dilution (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 2 Aug 2026.

About Hansa Biopharma AB

HNSA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr HNSA

Lightyear

Legal

Work with us

Bulls say / Bears say

Hansa Biopharma AB/Skr HNSA

About Hansa Biopharma AB

HNSA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Bulls say / Bears say